Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04520711
Title Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Providence Health & Services

Advanced Solid Tumor



CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells

Age Groups: adult | child | senior
Covered Countries USA

No variant requirements are available.